| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |